Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
03 05 2019
Historique:
entrez: 1 6 2019
pubmed: 1 6 2019
medline: 3 3 2020
Statut: epublish

Résumé

The Hospital Readmissions Reduction Program (HRRP) was recently expanded to penalize excessive readmissions after total hip arthroplasty (THA) and total knee arthroplasty (TKA). These are the first surgical procedures to be included in the HRRP. To determine whether the HRRP was associated with a greater decrease in readmissions after targeted procedures (THA and TKA) compared with similar nontargeted procedures (lumbar spine fusion and laminectomy). A retrospective cohort study was conducted of patients 50 years or older among all payers in the Nationwide Readmissions Database who underwent THA, TKA, lumbar spine fusion, or laminectomy between January 1, 2010, and September 30, 2015. Multivariable logistic regression and interrupted time-series models were used to calculate and compare 30-day readmission trends in 3 periods associated with the HRRP: preimplementation (January 2010-September 2012), implementation (October 2012-September 2014), and penalty (October 2014-September 2015). Statistical analysis was performed from January 1, 2010, to September 30, 2015. Announcement and implementation of the HRRP. Readmission within 30 days after hospitalization for THA, TKA, lumbar spine fusion, or laminectomy surgery. The study included 6 687 077 (58.3% women and 41.7% men; mean age, 66.7 years; 95% CI, 66.7-66.8 years) weighted hospitalizations for THA, TKA, lumbar spine fusion, and laminectomy surgery: 4 765 466 hospitalizations for targeted conditions and 1 921 611 for nontargeted conditions. After passage of the Patient Protection and Affordable Care Act, the risk-adjusted rates of readmission after all procedures decreased in a similar fashion. Implementation of the HRRP was associated with a 0.018% per month decrease in the rate of readmission (95% CI, -0.025% to -0.010%) after targeted procedures, which was not observed after nontargeted procedures (slope per month, -0.003%; 95% CI, -0.016% to 0.010%). Penalties were not associated with a greater decrease in readmission for either targeted or nontargeted procedures. These results appear to be consistent with hospitals responding to the future possibility of penalties by reducing readmissions after surgical procedures targeted by the HRRP.

Identifiants

pubmed: 31150074
pii: 2734801
doi: 10.1001/jamanetworkopen.2019.4634
pmc: PMC6547226
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e194634

Commentaires et corrections

Type : CommentIn

Références

Urology. 2019 Mar;125:86-91
pubmed: 30366043
Circulation. 2015 May 19;131(20):1796-803
pubmed: 25986448
N Engl J Med. 2016 Apr 14;374(15):1424-34
pubmed: 27074067
J Bone Joint Surg Am. 2005 Jul;87(7):1487-97
pubmed: 15995115
N Engl J Med. 2016 Apr 14;374(15):1413-23
pubmed: 27074066
Spine (Phila Pa 1976). 2013 May 15;38(11):916-26
pubmed: 23324922
World J Surg. 2019 Feb;43(2):534-539
pubmed: 30341470
JAMA Cardiol. 2018 Jan 1;3(1):44-53
pubmed: 29128869
J Bone Joint Surg Am. 2010 Aug 4;92(9):1884-9
pubmed: 20686063
Ann Surg. 2018 Apr;267(4):599-605
pubmed: 28657950
JAMA. 2016 Dec 27;316(24):2647-2656
pubmed: 28027367
JAMA Surg. 2018 Dec 1;153(12):1074-1076
pubmed: 30193351
N Engl J Med. 2016 Apr 21;374(16):1543-51
pubmed: 26910198
JAMA Surg. 2018 Mar 1;153(3):243-250
pubmed: 29167870
Ann Surg. 2017 Oct;266(4):617-624
pubmed: 28657948
JAMA Surg. 2018 Mar 1;153(3):251
pubmed: 29167865
PLoS One. 2015 Apr 17;10(4):e0123593
pubmed: 25884444
JACC Heart Fail. 2018 Jul;6(7):607-609
pubmed: 29957194
J Arthroplasty. 2014 Feb;29(2):256-60
pubmed: 23958236

Auteurs

Ashwin Ramaswamy (A)

Icahn School of Medicine at Mount Sinai, New York, New York.
Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Maya Marchese (M)

Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Alexander P Cole (AP)

Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Sabrina Harmouch (S)

Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

David Friedlander (D)

Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Joel S Weissman (JS)

Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Stuart R Lipsitz (SR)

Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Adil H Haider (AH)

Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Adam S Kibel (AS)

Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Andrew J Schoenfeld (AJ)

Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Quoc-Dien Trinh (QD)

Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH